 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H24N2O |
| Molar mass | 356.469 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NNE1 (also known asNNEI,MN-24 andAM-6527) is anindole-basedsynthetic cannabinoid, representing amolecular hybrid ofAPICA andJWH-018[1] that is anagonist for thecannabinoid receptors, withKi values of 60.09 nM atCB1 and 45.298 nM atCB2 andEC50 values of 9.481 nM at CB1 and 1.008 nM at CB2.[2] It was designed by Jos Lange atAbbott in 2010 to serve as an in vivo active pharmacological tool and has aCB1 receptor pEC50 of 8.9 with around 80x selectivity over the relatedCB2 receptor.[3] It is suspected that metabolic hydrolysis of the amide group of NNE1 may release1-naphthylamine, a knowncarcinogen, given the known metabolic liberation (and presence as an impurity) ofamantadine in the related compoundAPINACA, and NNE1 was banned in New Zealand in 2012 as atemporary class drug to stop it being used as an ingredient in then-legalsynthetic cannabis products.[4] NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.[5]
AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects.[6]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
